ADVENTRX Pharmaceuticals (ANX)
ADVENTRX Pharmaceuticals Revenue Growth
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these ANX related companies
ANX News
Bio amazing. $ROSG truly a run for the ages. Just holding my small bios $ABIO and $ANX. Be interesting to see if ASCO conference pops them.
about 3 days ago by GarethSoloway
about 3 days ago by GarethSoloway
ADVENTRX Pharmaceuticals to Sponsor & Present at the Martin Center's 2012 Sickle Cell Disease Conference
Apr 16, 8:00AM PR Newswire
Apr 16, 8:00AM PR Newswire
RT @VistaPResearch $ANX Vista Partners Updates Coverage on ADVENTRX Pharmaceuticals; $3.50 Target Price http://stks.co/2zLU
about 67 days ago by StockCowboy
about 67 days ago by StockCowboy
Vista Partners Updates Coverage on ADVENTRX Pharmaceuticals, Inc.; $3.50 Target Price
Mar 21, 9:15AM PR Newswire
Mar 21, 9:15AM PR Newswire
@adamfeuerstein $ANX is ABSOLUTE GARBAGE ! All they do is print paper and pay out banking fees. Culley is a JOKE!!
about 73 days ago by Bullbear123
about 73 days ago by Bullbear123
@StockCowboy $ANX Probably won't have a repeat tomorrow. 150M shelf offering.
about 80 days ago by Random_Walk
about 80 days ago by Random_Walk
RT @GarethSoloway Nice day on $ANX. Market otherwise so quiet. Volume 71.5M. Nuts.
about 80 days ago by InTheMoneyStocks
about 80 days ago by InTheMoneyStocks
ADVENTRX Pharmaceuticals to Present at the 14th Annual BIO CEO & Investor Conference on February 14
Feb 07, 8:00AM PR Newswire
Feb 07, 8:00AM PR Newswire
Biotech Sector on the Upswing -- Dendreon and ADVENTRX Pharmaceuticals Looking Strong
Jan 31, 8:20AM Marketwire
Jan 31, 8:20AM Marketwire
Vista Partners Updates Coverage on ADVENTRX Pharmaceuticals, Inc.; $3.50 Target Price
Dec 15, 9:21AM Benzinga
Dec 15, 9:21AM Benzinga
ADVENTRX (ANX) Discusses ANX-188 Phase 3 Structure w/ FDA; Additional Info Needed for Finalization
Dec 01, 8:40AM Street Insider
Dec 01, 8:40AM Street Insider
Speculative Healthcare Companies IntelGenx and Adventrx Begin to Gain Ground
Nov 15, 8:16AM Marketwire
Nov 15, 8:16AM Marketwire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ANX | 0.535 | -0.01 | -0.93% | 25.53M |
| ANW | 5.27 | +0.01 | +0.19% | 243.63M |
| ANV | 27.47 | -0.20 | -0.72% | 2.463B |
| ASEI | 49.46 | +1.29 | +2.68% | 441.18M |
| ASCMA | 52.78 | +1.12 | +2.17% | 710.95M |
| ASCA | 18.42 | +0.13 | +0.71% | 605.47M |
| ASBC | 12.76 | -0.04 | -0.31% | 2.229B |
| ASA | 22.96 | +0.22 | +0.97% | |
| ARX | 6.54 | +0.01 | +0.15% | 554.72M |
| ARWRD | 4.120 | -0.05 | -1.20% |
